Lukas Müller, Jana Korb, Tobias Bäuerle, Tobias Jorg
{"title":"[Enteral contrast agents-When, what and how?]","authors":"Lukas Müller, Jana Korb, Tobias Bäuerle, Tobias Jorg","doi":"10.1007/s00117-026-01671-x","DOIUrl":"https://doi.org/10.1007/s00117-026-01671-x","url":null,"abstract":"<p><strong>Background: </strong>Administration of enteral contrast media (CM) in abdominal computed tomography (CT) is handled inconsistently across Germany.</p><p><strong>Objective: </strong>To present the current recommendations on administration of enteral contrast agents along the guiding questions of when, what and how and to translate them into radiological practice.</p><p><strong>Material and methods: </strong>Synthesis of indication-based recommendations, CM classes and their technical properties and the practical execution of both routes of administration, based on the recommendations of the German Röntgen Society (DRG), current guidelines, published evidence and institutional practice.</p><p><strong>Results: </strong>Positive oral CMs are obsolete for most abdominal indications, including acute abdomen, ileus and trauma, and are contraindicated when gastrointestinal bleeding or ischemia is suspected. In cases of suspected perforation, routine oral contrast agents should be omitted and barium sulphate is contraindicated, whereas water-soluble iodinated agents remain an option when a leak has to be specifically demonstrated. Furthermore, enteral contrasting with neutral oral CM remains useful for upper gastrointestinal tumor staging and enterography (preferably magnetic resonance enterography).</p><p><strong>Conclusion: </strong>An indication-appropriate, guideline-based enteral contrast agent administration reduces unnecessary burden without compromising diagnostic accuracy and should be embedded in standardized workflows.</p>","PeriodicalId":74635,"journal":{"name":"Radiologie (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Contrast agent strategies in elective oncological imaging].","authors":"Mirjam Gerwing, Michel Eisenblätter","doi":"10.1007/s00117-026-01670-y","DOIUrl":"https://doi.org/10.1007/s00117-026-01670-y","url":null,"abstract":"<p><p>Computed tomography (CT) and magnetic resonance imaging (MRI) are central to staging, treatment planning and response assessment in oncology. For many tumor entities, clinical guidelines specify the recommended imaging frequency and appropriate modality; however, the practical implementation, including the applied imaging protocols, varies in clinical routine. Intravenous contrast agents are indispensable in oncological imaging for a variety of specific clinical questions, particularly for the detection and characterization of intraparenchymal lesions. In addition to the general indications for contrast administration, the selection of the optimal contrast phase for subsequent imaging is crucial. This article outlines the fundamentals of iodine-based and gadolinium-based contrast agents, their pharmacokinetics and safety aspects that should be considered in the context of a risk-benefit assessment for their use in oncological imaging. Furthermore, typical contrast phases and imaging protocols are presented as representative examples. Future developments in this field include spectral imaging and photon-counting CT, quantitative imaging and artificial intelligence (AI)-based methods as well as contrast agent-free functional MRI techniques. All of these approaches aim to achieve more precise tissue characterization, a potential reduction of radiation dose and/or contrast agent use as well as automated optimization of image acquisition and interpretation and are also discussed in this article.</p>","PeriodicalId":74635,"journal":{"name":"Radiologie (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Prostate artery embolization-2026 update : Technique, evidence, and role in the treatment of benign prostatic hyperplasia].","authors":"P Schott, M Katoh","doi":"10.1007/s00117-026-01672-w","DOIUrl":"https://doi.org/10.1007/s00117-026-01672-w","url":null,"abstract":"<p><strong>Clinical/methodical issue: </strong>Benign prostatic syndrome is the most common urologic condition in older men and substantially affects quality of life.</p><p><strong>Standard radiological methods: </strong>Early stage disease is managed with pharmacotherapy. In advanced disease, transurethral resection is the surgical standard.</p><p><strong>Methodical innovations: </strong>For more than 10 years, prostatic artery embolization has provided a minimally invasive alternative performed under local anesthesia.</p><p><strong>Performance: </strong>Randomized trials and meta-analyses document a marked improvement in symptom score and quality of life with lower periprocedural morbidity than transurethral resection. Five-year data confirm durable symptom improvement, albeit with a higher reintervention rate than the surgical reference standard. Compared with combined medical therapy, embolization proved superior in a randomized trial. Unlike transurethral resection, there is no upper prostate volume limit.</p><p><strong>Achievements: </strong>With its inclusion in national and international guidelines, prostatic artery embolization has left the experimental stage.</p><p><strong>Practical recommendations: </strong>Detailed knowledge of the pelvic vascular anatomy and a clear imaging and navigation strategy are prerequisites. Avoidance of nontarget embolization is the central safety element. Novel embolic agents and potential expansion of indications are undergoing clinical evaluation.</p>","PeriodicalId":74635,"journal":{"name":"Radiologie (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149129494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paul Reidler, Daniel Friedrich, Michael Winkelmann
{"title":"[Differential diagnoses of malignant bone marrow diseases].","authors":"Paul Reidler, Daniel Friedrich, Michael Winkelmann","doi":"10.1007/s00117-026-01645-z","DOIUrl":"10.1007/s00117-026-01645-z","url":null,"abstract":"<p><strong>Background: </strong>Bone marrow abnormalities are frequent radiological findings with a broad spectrum ranging from physiological conversion/reconversion to malignant infiltration.</p><p><strong>Objective: </strong>This article summarizes important differential diagnoses of malignant bone marrow lesions and presents a practical diagnostic approach.</p><p><strong>Material and methods: </strong>Narrative review based on the current literature, focusing on magnetic resonance imaging (MRI), computed tomography (CT) and supplementary techniques, such as chemical-shift imaging (CSI), Dixon sequences, diffusion-weighted imaging (DWI) and positron emission tomography CT (PET/CT).</p><p><strong>Results: </strong>Non-fat-suppressed T1-weighted MRI is central for bone marrow assessment. A signal intensity lower than skeletal muscle or intervertebral discs argues against simple reconversion and should raise the suspicion of infiltration. The CSI and Dixon techniques help differentiate benign mimics by demonstrating intralesional fat. Important differential diagnoses include metastases, leukemia, lymphomas, myeloproliferative disorders, multiple myeloma, reconversion, bone infarcts, chronic nonbacterial osteitis (CNO)/chronic recurrent multifocal osteomyelitis (CRMO), Langerhans-cell histiocytosis (LCH), enostosis and osteomyelitis.</p><p><strong>Conclusion: </strong>The diagnosis requires integration of imaging patterns, fat content, mineralization, age, clinical context, tumor history and course. In unclear or aggressive findings, imaging follow-up or biopsy is required.</p>","PeriodicalId":74635,"journal":{"name":"Radiologie (Heidelberg, Germany)","volume":" ","pages":"773-783"},"PeriodicalIF":0.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148431690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Imaging in monoclonal plasma cell disorders : Multiple myeloma, smouldering multiple myeloma and MGUS].","authors":"Jakob Neubauer","doi":"10.1007/s00117-026-01646-y","DOIUrl":"10.1007/s00117-026-01646-y","url":null,"abstract":"<p><strong>Background: </strong>Imaging has a key diagnostic role in monoclonal plasma cell disorders. It can be used not only to detect osteolytic skeletal lesions but also for the detection of bone marrow involvement, extramedullary manifestations, impending complications, treatment response and the relapse assessment. Whole-body computed tomography (CT) has replaced the conventional skeletal survey, while whole-body magnetic resonance imaging (MRI) and <sup>18</sup>F-fluorodeoxyglucose positron emission tomography-CT (FDG PET/CT) supplement the morphological skeletal assessment by depicting the bone marrow and functional-metabolic disease activity.</p><p><strong>Objective: </strong>This article provides a practical, guideline-based overview of imaging in monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple myeloma (SMM) and active (requiring treatment) multiple myeloma (MM), focusing on the indications, technical implementation, interpretation of results, structured reporting and clinical consequences.</p><p><strong>Material and methods: </strong>Narrative synthesis of relevant publications and guidelines, including literature available through June 2026.</p><p><strong>Results: </strong>In cases of active MM, whole-body CT is recommended at the time of making the diagnosis to assess skeletal damage. Whole-body MRI or 18F-FDG PET/CT can be additionally used to evaluate bone marrow involvement, metabolic activity and paraskeletal or extramedullary disease manifestations. In selected non-IgM MGUS with a high risk of progression according to the German S3 algorithm and in SMM, whole-body CT is primarily used to differentiate from MM. If osteolysis is not detected, whole-body MRI or alternatively 18F-FDG PET/CT is performed. More than one focal MRI lesion typical for myeloma each measuring ≥ 5 mm is a myeloma-defining event. Follow-up and response to treatment should preferentially use the modality that best depicted the baseline disease. In serologically measurable disease, follow-up is predominantly clinical and laboratory-based. Imaging follow-up is required in hyposecretory or nonsecretory MM, in patients with new clinical symptoms, or in the presence of soft-tissue involvement.</p><p><strong>Conclusion: </strong>Radiological imaging reports of plasma cell disorders should be standardized in a way specific for the modality and directed at the clinical issue. Decisive is the distinction between mineralized bone and bone marrow, the assessment of instability risk, the separate description of paraskeletal and true extramedullary manifestations as well as the transparent classification of the response, stable findings or progression. A structured whole-body reporting facilitates interdisciplinary treatment planning in the myeloma board.</p>","PeriodicalId":74635,"journal":{"name":"Radiologie (Heidelberg, Germany)","volume":" ","pages":"752-763"},"PeriodicalIF":0.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148633043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Imaging diagnostics of kidney tumors : Scores and classification systems].","authors":"Andreas H Mahnken","doi":"10.1007/s00117-026-01662-y","DOIUrl":"10.1007/s00117-026-01662-y","url":null,"abstract":"<p><p>Renal cell carcinoma is one of the most common cancers and its mortality rate is falling due to continuous advances in diagnostics and treatment. Early detection using imaging techniques enables treatment with curative intent, resulting in a correspondingly favorable prognosis. Classification systems such as the TNM and Bosniak classifications as well as nephrometric scores, particularly the R.E.N.A.L. score, assist in prognosis assessment and support individualized treatment planning. They help to assess tumor complexity and the subsequent risk of postoperative or postinterventional complications; however, other anatomical and clinical factors, apart from nephrometric scores, must also be considered for an optimal individual treatment decision.</p>","PeriodicalId":74635,"journal":{"name":"Radiologie (Heidelberg, Germany)","volume":" ","pages":"797-807"},"PeriodicalIF":0.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148972400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Markus Uhl, Simon Wiedemann, Sebastian Berg, Benedict Oerther
{"title":"[Special aspects of magnetic resonance imaging of pediatric bone marrow].","authors":"Markus Uhl, Simon Wiedemann, Sebastian Berg, Benedict Oerther","doi":"10.1007/s00117-026-01570-1","DOIUrl":"10.1007/s00117-026-01570-1","url":null,"abstract":"<p><strong>Clinical/methodical issue: </strong>Bone marrow development is age-dependent. The transformation from red to yellow bone marrow follows a constant pattern and influences the localization and morphology of bone marrow processes.</p><p><strong>Standard radiological methods: </strong>Magnetic resonance imaging (MRI) is an adequate imaging method to obtain information about the composition of bone marrow.</p><p><strong>Methodical innovations: </strong>Different MRI sequences allow the differentiation between physiologic, reactive, benign, and pathologic bone marrow changes.</p>","PeriodicalId":74635,"journal":{"name":"Radiologie (Heidelberg, Germany)","volume":" ","pages":"764-772"},"PeriodicalIF":0.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146151380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Metabolism and bone marrow : Imaging of physiological and pathological processes].","authors":"Maximilian T Löffler, Nico Sollmann","doi":"10.1007/s00117-026-01639-x","DOIUrl":"10.1007/s00117-026-01639-x","url":null,"abstract":"<p><strong>Clinical/methodical issue: </strong>Human bone marrow and its metabolism-particularly the composition of bone marrow adipose tissue (BMAT)-are subject to physiological changes throughout the lifespan. However, they are also involved in and altered by pathological processes. Modern techniques of quantitative magnetic resonance imaging (MRI) now enable an objective and quantitative evaluation of such processes.</p><p><strong>Standard radiological methods: </strong>Standard radiological procedures consist of T1- and T2-weighted MRI of the bone (marrow).</p><p><strong>Methodical innovations: </strong>Methodological innovations consist of chemical shift encoding-based (CSE) water-fat imaging and proton (<sup>1</sup>H) MR spectroscopy (MRS).</p><p><strong>Performance: </strong>In particular, quantification using the proton density fat fraction (PDFF) is of relevance for both physiological and pathological changes of BMAT.</p><p><strong>Achievements: </strong>The determination of the PDFF-particularly by means of (<sup>1</sup>H)-MRS-is increasingly being used for the evaluation of BMAT, but it remains a non-standard procedure.</p><p><strong>Practical recommendations: </strong>Knowledge of the typical signal characteristics of BMAT is essential for reliably discriminating physiological from pathological changes-both in terms of visual image reading and quantification.</p>","PeriodicalId":74635,"journal":{"name":"Radiologie (Heidelberg, Germany)","volume":" ","pages":"745-751"},"PeriodicalIF":0.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148450999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Incidental bone marrow findings].","authors":"Simone Schüle, Carsten Hackenbroch","doi":"10.1007/s00117-026-01642-2","DOIUrl":"10.1007/s00117-026-01642-2","url":null,"abstract":"<p><strong>Background: </strong>Bone marrow incidentalomas are being detected with increasing frequency due to the growing use of magnetic resonance imaging (MRI). It is essential to distinguish benign from malignant lesions that require further investigation.</p><p><strong>Objectives: </strong>The aim is to describe the imaging characteristics to facilitate the practical differentiation between malignant and benign incidental findings in bone marrow.</p><p><strong>Methods: </strong>A narrative literature review focusing on a pattern-based approach to the spinal and extraspinal skeleton.</p><p><strong>Results: </strong>The signal characteristics, morphology, and location of the bone marrow incidentaloma are crucial for classifying the lesion. In the spine, classifying the lesion as diffuse, focal, microfocal, or regional helps limit the differential diagnoses. Osteolytic lesions are hypointense on T1w- and hyperintense on T2w-imaging; sclerotic lesions are signal-free on all sequences; and fatty lesions are hyperintense on both T1w- and T2w-imaging. The presence of micro- or macroscopic fat within a lesion is a criterion for benignity.</p><p><strong>Conclusion: </strong>By using a few MRI sequences and correlating them with X‑ray and computed tomography (CT) images, it is possible to reliably classify incidental bone marrow lesions.</p>","PeriodicalId":74635,"journal":{"name":"Radiologie (Heidelberg, Germany)","volume":" ","pages":"784-792"},"PeriodicalIF":0.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}